Novel SHP2 degrader SHP2-D26 in combination with the EGFR inhibitor osimertinib (AZD9291) could overcome osimertinib resistance in NSCLC by reducing MCL-1 expression [38]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.